Literature DB >> 29599383

Ethics of a therapeutic trial: addressing limitations of an active intervention in optic nerve lymphoma.

Rohan Bir Singh1,2, Sahil Thakur2, Parul Ichhpujani2, Suresh Kumar2.   

Abstract

We report a unique case of optic nerve lymphoma after completion of chemotherapy for non-Hodgkin's lymphoma. The uncommon nature of presentation, our therapeutic dilemma and the further course of treatment are reported. In cases with extremely poor prognosis, unnecessary treatment puts additional strain both financially and psychologically on the patients and their family. Therapeutic focus should be on hospice care and family counselling. The decision to not treat is a crucial component of cancer management; however, the ethics of this decision are yet to be suitably addressed by the literature. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  chemotherapy; ethics; ophthalmology; radiotherapy; visual pathway

Mesh:

Year:  2018        PMID: 29599383      PMCID: PMC5878265          DOI: 10.1136/bcr-2018-224217

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  It is "too late" or is it? Bereaved family member perceptions of hospice referral when their family member was on hospice for seven days or less.

Authors:  Joan M Teno; David Casarett; Carol Spence; Stephen Connor
Journal:  J Pain Symptom Manage       Date:  2012-01-30       Impact factor: 3.612

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

Review 4.  Isolated optic nerve infiltration in systemic lymphoma--a case report and review of literature.

Authors:  Usha R Kim; Akash D Shah; Vipul Arora; Urvashi Solanki
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2010 Jul-Aug       Impact factor: 1.746

5.  Collusion in doctor-patient communication about imminent death: an ethnographic study.

Authors:  A M The; T Hak; G Koëter; G van der Wal
Journal:  West J Med       Date:  2001-04

Review 6.  Optic nerve lymphoma: report of two cases and review of the literature.

Authors:  Jennifer L Kim; Pia R Mendoza; Alia Rashid; Brent Hayek; Hans E Grossniklaus
Journal:  Surv Ophthalmol       Date:  2014-12-18       Impact factor: 6.048

7.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

8.  Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases.

Authors:  F R MacKintosh; T V Colby; W J Podolsky; J S Burke; R T Hoppe; F P Rosenfelt; S A Rosenberg; H S Kaplan
Journal:  Cancer       Date:  1982-02-01       Impact factor: 6.860

9.  Patient perceptions of an outpatient palliative care intervention: "It had been on my mind before, but I did not know how to start talking about death...".

Authors:  Michael W Rabow; Karen Schanche; Jane Petersen; Suzanne L Dibble; Stephen J McPhee
Journal:  J Pain Symptom Manage       Date:  2003-11       Impact factor: 3.612

10.  How do physicians decide to treat: an empirical evaluation of the threshold model.

Authors:  Benjamin Djulbegovic; Shira Elqayam; Tea Reljic; Iztok Hozo; Branko Miladinovic; Athanasios Tsalatsanis; Ambuj Kumar; Jason Beckstead; Stephanie Taylor; Janice Cannon-Bowers
Journal:  BMC Med Inform Decis Mak       Date:  2014-06-05       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.